versus placebo or control
No demonstrated result for efficacy
Vasc events 0.21 [0.05; 0.91]
cardiovascular events 0.21 [0.05; 0.91]
Vasc deaths 0.21 [0.02; 1.72]
Non-fatal MI 0.21 [0.02; 1.72]
trapidil (n=71)
vs.
(n=73)
Sample size: 71/73
Primary endpoint:
FU duration: 6m